Time filter

Source Type

Grant
Agency: Cordis | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-IAPP-2008 | Award Amount: 1.48M | Year: 2009

The main objective of this project is to develop a research network that includes both private and public institutions focused on the exchange of expertise in imaging, genomics and bioinformatics to be utilized in monitoring therapies and disease progression in severe allergic asthma (AA): Aeirtec, a research-service SME with Hu-SCID in vivo models of AA that would benefit from academic expertise in high tech imaging and immunology Marinomed, an SME with novel compounds potentially relevant to AA, in need of in vivo models as well as genomics and imaging technologies aimed at validating its compounds CBM, an SME with expertise in genomics as well as IP exploitation and business development, managing a biotech cluster, in need of furthering its imaging expertise as well as its competence in AA models UMG-GOE is a university which provides strong expertise in the imaging field, in need of bioinformatics support as well as specific expertise on AA models MUW is an academic partner with expertise in in vivo models of AA and in the basic immunology underlying the disease that will advance their research objectives with novel therapeutics to study and from expertise in genomics and imaging. The combined expertise and transfer of knowledge between academic and industrial partners will have an impact on the scientific community and on exploitation and commercialization.The main scientific and technological objectives will encompass: 1. Development of novel optical imaging techniques and genomic biomarkers for severe AA 2. Identification of potential biomarkers useful for clinical monitoring of therapeutic efficacy of novel compounds in ththe treatment of severe AA 3. Development of novel high resolution molecular imaging techniques in animal models of AA 4. Bioinformatics support in the acquisition, management, archiving, and analysis of imaging and genomics data


Markus M.A.,University of Gottingen | Dullin C.,University of Gottingen | Mitkovski M.,Max Planck Institute for Experimental Medicine | Prieschl-Grassauer E.,Marinomed Biotechnologie GmbH | And 3 more authors.
PLoS ONE | Year: 2014

Background: Molecular imaging of lung diseases, including asthma, is limited and either invasive or non-specific. Central to the inflammatory process in asthma is the recruitment of eosinophils to the airways, which release proteases and proinflammatory factors and contribute to airway remodeling. The aim of this study was to establish a new approach to non-invasively assess lung eosinophilia during the course of experimental asthma by combining non-invasive near-infrared fluorescence (NIRF) imaging with the specific detection of Siglec-F, a lectin found predominantly on eosinophils. Methodology/Principal Findings: An ovalbumin (OVA)-based model was used to induce asthma-like experimental allergic airway disease (EAAD) in BALB/c mice. By means of a NIRF imager, we demonstrate that 48 h-72 h after intravenous (i.v.) application of a NIRF-labeled anti-Siglec-F antibody, mice with EAAD exhibited up to 2 times higher fluorescence intensities compared to lungs of control mice. Furthermore, average lung intensities of dexamethasone-treated as well as beta-escin-treated mice were 1.8 and 2 times lower than those of untreated, EAAD mice, respectively and correlated with the reduction of cell infiltration in the lung. Average fluorescence intensities measured in explanted lungs confirmed the in vivo findings of significantly higher values in inflamed lungs as compared to controls. Fluorescence microscopy of lung cryosections localized the i.v. applied NIRF-labeled anti-Siglec-F antibody predominantly to eosinophils in the peribronchial areas of EAAD lungs as opposed to control lungs. Conclusion/Significance: We show that monitoring the occurrence of eosinophils, a prominent feature of allergic asthma, by means of a NIRF-labeled antibody directed against Siglec-F is a novel and powerful non-invasive optical imaging approach to assess EAAD and therapeutic response in mice over time. © 2014 Markus et al.


Sipos W.,University of Veterinary Medicine Vienna | Reutterer B.,Marinomed Biotechnologie GmbH | Frank M.,Marinomed Biotechnologie GmbH | Unger H.,University of Veterinary Medicine Vienna | And 3 more authors.
International Archives of Allergy and Immunology | Year: 2013

Background: Current standard medications for the treatment of allergic inflammation consist primarily of glucocorticoids and anti-histamines, but adverse side effects or insufficient responsiveness by patient subpopulations illustrate the need for safe and novel alternatives. Thus, there is a demand to develop a porcine model that is able to mimic mast cell-mediated type I hypersensitivity. Previously, we found that escin, a pharmacologically active mix of triterpene saponins from horse chestnut extracts, exerts anti-allergic effects in murine models and merits further investigation as an anti-allergic therapeutic. Methods: We developed a new porcine model of allergic dermatitis based on a clinical prick test protocol. Histamine clearly provoked erythema and swelling at the prick site, whereas the mast cell-degranulating compound 48/80 even more pronounced caused wheal and flare reactions known from the human prick response. This model was used to test the anti-allergic efficacy of orally applied escin. Results: Oral pretreatment of animals with escin strongly inhibited the allergic skin response induced by compound 48/80 in a dose-dependent manner. Additional in vitro data from murine mast cells indicate an engagement of the glucocorticoid receptor pathway upon treatment with escin. Conclusions: This model provides a valuable and easy-to-set-up tool for preclinical studies of mast cell-inhibiting compounds. The successful implementation of this model supports the development of oral escin applications as a novel anti-allergic therapy. © 2012 S. Karger AG, Basel.


Eccles R.,University of Cardiff | Meier C.,Marinomed Biotechnologie GmbH | Jawad M.,University of Cardiff | Weinmullner R.,Marinomed Biotechnologie GmbH | And 2 more authors.
Respiratory Research | Year: 2010

Background: The common cold, the most prevalent contagious viral disease in humans still lacks a safe and effective antiviral treatment. Iota-Carrageenan is broadly active against respiratory viruses in-vitro and has an excellent safety profile. This study investigated the efficacy and safety of an Iota-Carrageenan nasal spray in patients with common cold symptoms.Methods: In a randomized, double-blind, placebo-controlled exploratory trial, 35 human subjects suffering from early symptoms of common cold received Iota-Carrageenan (0.12%) in a saline solution three times daily for 4 days, compared to placebo.Results: Administration of Iota-Carrageenan nasal spray reduced the symptoms of common cold (p = 0.046) and the viral load in nasal lavages (p = 0.009) in patients with early symptoms of common cold. Pro-inflammatory mediators FGF-2, Fractalkine, GRO, G-CSF, IL-8, IL-1α, IP-10, IL-10, and IFN-α2 were reduced in the Iota-Carrageenan group.Conclusions: Iota-Carrageenan nasal spray appears to be a promising treatment for safe and effective treatment of early symptoms of common cold. Larger trials are indicated to confirm the results. © 2010 Eccles et al; licensee BioMed Central Ltd.


Patent
Marinomed Biotechnologie Gmbh | Date: 2012-05-30

The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus, The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.


Patent
Marinomed Biotechnologie Gmbh | Date: 2010-12-17

The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.


Patent
Marinomed Biotechnologie Gmbh | Date: 2012-08-23

Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.


Patent
Marinomed Biotechnologie Gmbh | Date: 2011-09-19

The present invention relates to pharmaceutical compositions for administration to the respiratory tract, the gastrointestinal tract or the eyes. In particular, the invention relates to liquid formulations and dry powder compositions comprising carrageenan, and in particular iota and kappa carrageenan, and one or more therapeutic agents. These sprays, powders, and the gel that forms when they are administered to the respiratory tract, the gastrointestinal tract or the eyes, have now surprisingly been found to be a very effective way of prevention and treatment of type I allergies and intranasal administration of therapeutic agents.


Patent
Marinomed Biotechnologie GmbH | Date: 2010-05-19

The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment of a Type IV hypersensitivity reaction or symptoms of a Type IV hypersensitivity reaction, such as diseases selected from contact dermatitis, atopic dermatitis, hypersensitivity pneumonitis, chronic transplant rejection, graft versus host disease, cell mediated autoimmune diseases, Hashimotos thyroiditis, Sjogrens disease, adrenalitis, polymyositis, or pernicious anemia.


Patent
Marinomed Biotechnologie Gmbh | Date: 2016-09-30

The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.

Loading Marinomed Biotechnologie GmbH collaborators
Loading Marinomed Biotechnologie GmbH collaborators